BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock News

USA - NASDAQ:BIAF - US09076W1099 - Common Stock

1.84 USD

-0.04 (-2.13%)

Last: 11/14/2025, 8:00:01 PM

1.7 USD

-0.14 (-7.61%)

After Hours: 11/14/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BIAF Latest News, Press Relases and Analysis

All

Press Releases

19 hours ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

10 days ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

18 days ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

2 months ago - By: Stocktwits - Mentions: VXF

News Image

bioAffinity Technologies Stock Surged A Whopping 56% Today – Here’s An Important Update

26 days ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

a month ago - By: Benzinga

Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains?

a month ago - By: Benzinga - Mentions: SBFM ADAP GNPX HYPR ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

a month ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

a month ago - By: WallachBeth Capital LLC

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

a month ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

a month ago - By: WallachBeth Capital LLC

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

a month ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

a month ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

2 months ago - By: WallachBeth Capital LLC

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

2 months ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

2 months ago - By: WallachBeth Capital LLC

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

2 months ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

2 months ago - By: bioAffinity Technologies, Inc.

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung